Table 1.
Anti-inflammatory drugs used in this study.
| Dose (mg/kg) | Resuspended/dissolved | Supplied | Target | |
|---|---|---|---|---|
| Indomethacin | 15 | 0.2 M Tris–HCl, pH 8 | Sigma | COX-1/2 |
| Ibuprofen | 30 | Saline | Sigma | COX-1/2 |
| Dexamethasone | 2 | Saline | Sigma | NFκB |
| Paracetamol | ||||
| (acetaminophen) | 20 | Saline | Sigma | COX |
| Ozagrel | 5 | Saline | Sigma | TBX synthase |
| Picotamide | 85 | 10% DMSO/saline | Sigma | TBX synthase |
| BM 567 | 5 | 10% DMSO/saline | Cayman | TBX synthase |
| Furegrelate | 10 | Saline | Cayman | TBX receptor |
| Ciglitazone | 10 | 10% DMSO/saline | Cayman | PPAR-γ |
| Piroxicam | 10 | 0.2 M Tris–HCl, pH 8 | Sigma | COX-1 |
| Nimesulide | 10 | 0.2 M Tris–HCl, pH 8 | Sigma | COX-2 |
| Niflumic acid | 10 | 0.2 M Tris–HCl, pH 8 | Sigma | COX-2 |
| Sulindac | 10 | 0.2 M Tris–HCl, pH 8 | Sigma | COX-1 |
Mice were pre-treated with anti-inflammatory drugs at the dose indicated by intra-peritoneal injection, 30–60 min prior to LPS administration. A minimum of n = 3 per group was used.